Allovir (ALVR) Stock Up On RMAT Designation

Allovir (ALVR) is today’s Under 30-stock. In this segment Jenny Horne and Alex Coffey discuss Allovir (ALVR) which is a late clinical-stage allogeneic T cell immunotherapy company. Jenny and George Tsilis talk the announcement Wednesday that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allovir’s (ALVR) investigative T cell therapy posoleucel, a therapy designed to treat infections and diseases from six common viruses. An RMAT designation means a faster, more streamlined approval process. Alex and George talk about how the news resulted in Allovir’s (ALVR) biggest trading day ever yesterday.